S2Medical AB (publ) has signed a distribution agreement for the Iranian market with Avije Teb Parsin. The agreement covers the company's skin substitute Epiprotect and involves initial orders of a total of approximately SEK 740,000 as well as obligations for further orders of approximately SEK 10.6 million up to and including 2026. The initial order is subject to registration of the product and is expected to be shipped in approximately 6 months.
Iran, with its almost 90 million inhabitants, is one of the region's most populous countries. In 2019, there were 15 specialized burn units in the country and a 2011 survey showed that over 11% of the country's population suffers from diabetes, which was a 35% increase compared to 2005. Overall, this makes Iran a significant market for wound healing products such as Epiprotect.
"Since the establishment of our sales office in the Middle East, we have expanded our network of distributors to most countries in the GCC region. We see Iran as a complex market with great potential and look forward to building a strategy for the implementation of Epiprotect together with our new distributor. " says the company's COO Mårten Skog.
This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-05-2023 13:33 CET.